Teva Recalls Migraine Transdermal Patch
Teva Pharmaceutical Industries, Ltd. plans to voluntarily suspend sales, marketing, and distribution of Zecuity (sumatriptan iontophoretic transdermal system). Teva has received post-marketing reports of application site reactions described as burns and scars in patients treated with Zecuity and is working with the US Food and Drug Administration (FDA) to better understand these adverse events. In addition to this voluntary suspension, Teva has initiated a pharmacy-level recall of the product.
Source: Teva Pharmaceutical Industries